share_log

Johnson & Johnson | 3: Initial statement of beneficial ownership of securities-10% Owner JOHNSON & JOHNSON

Johnson & Johnson | 3: Initial statement of beneficial ownership of securities

强生 | 3：首次持股声明
SEC announcement ·  04/10 17:06
Moomoo AI 已提取核心信息
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
大型医疗保健公司强生公司已向美国证券交易委员会提交了3号表格，其中显示了证券实益所有权的初步声明。这份日期为2024年9月4日的文件显示，强生通过其全资子公司强生创新——JJDC, Inc. 已成为Contineum Therapeutics, Inc. 的10％所有者，拥有1,979,173股A类普通股的间接实益所有权。该文件由强生公司秘书马克·拉金斯签署，强调了该公司对Contineum Therapeutics的重大投资。
大型医疗保健公司强生公司已向美国证券交易委员会提交了3号表格，其中显示了证券实益所有权的初步声明。这份日期为2024年9月4日的文件显示，强生通过其全资子公司强生创新——JJDC, Inc. 已成为Contineum Therapeutics, Inc. 的10％所有者，拥有1,979,173股A类普通股的间接实益所有权。该文件由强生公司秘书马克·拉金斯签署，强调了该公司对Contineum Therapeutics的重大投资。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息